COPD and Triple Therapy – When We Should and Shouldn’t Use It
COPD and Triple Therapy – When We Should and Shouldn't Use It is an essential course designed for healthcare professionals to better understand Chronic Obstructive Pulmonary Disease (COPD) and the role of triple therapy in its management. This course provides an in-depth look at COPD, a common and often underdiagnosed lung disease, and examines the evidence-based guidelines for using triple therapy, which combines three different medications to manage symptoms and reduce exacerbations. Participants will learn when triple therapy is indicated and when it should be avoided, based on current clinical guidelines and patient-specific factors. The course also covers the pharmacological mechanisms of the drugs used in triple therapy, including inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs), and their respective roles in managing COPD.
.jpg)
Learning Outcomes
What you'll learn
- Understand the pathophysiology of COPD and its impact on lung function.
- Identify the indications for using triple therapy in COPD management.
- Recognize when triple therapy is not appropriate for COPD patients.
- Differentiate between the pharmacological actions of ICS, LABAs, and LAMAs.
- Apply current clinical guidelines and evidence to determine when to start or discontinue triple therapy.
- Educate patients on the benefits and potential risks of triple therapy for COPD.
Stay updated with our
Learning Outcomes
What you'll learn
- Understand the pathophysiology of COPD and its impact on lung function.
- Identify the indications for using triple therapy in COPD management.
- Recognize when triple therapy is not appropriate for COPD patients.
- Differentiate between the pharmacological actions of ICS, LABAs, and LAMAs.
- Apply current clinical guidelines and evidence to determine when to start or discontinue triple therapy.
- Educate patients on the benefits and potential risks of triple therapy for COPD.
Stay updated with our
Training Overview
- Introduction to Chronic Obstructive Pulmonary Disease (COPD)
- COPD Management – The Role of Medications
- Triple Therapy in COPD – What It Is and How It Works
- When Should Triple Therapy Be Used?
- When Should Triple Therapy Be Avoided?
- Monitoring and Adjusting COPD Treatment with Triple Therapy
- Summary
.jpg)
.jpg)
.jpg)
.jpg)
Top reviews
No reviews yet.
You May Also Like
.jpg)
.jpg)
.jpg)
Take Your
Learning Anywhere
Stay on top of your learning with the Care Learning app.
Are you a qualified
Trainer or Instructor?
Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.
Refer a Friend &
Earn Rewards.
Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.
Frequently asked questions
Triple therapy includes inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs). Together, they improve lung function and reduce exacerbations in COPD patients.
Triple therapy is typically initiated for COPD patients with frequent exacerbations despite dual therapy with a LABA and LAMA or those with severe symptoms, as per the GOLD classification.
Potential risks include pneumonia, oral thrush, and osteoporosis, especially with long-term use of ICS. It's important to weigh the benefits of triple therapy against these risks.
Yes, triple therapy may be appropriate for patients with asthma-COPD overlap, particularly if they have frequent exacerbations despite standard treatments.
Patients on triple therapy should be monitored regularly through follow-up visits, spirometry, and symptom assessments. Adjustments to the therapy may be necessary based on patient progress and side effects.
Yes, triple therapy may be discontinued if the patient is not benefiting from it or experiences significant side effects. Alternative treatments can be considered based on the patient’s needs.